97/100BResMed stock forecast 2027–2031
Analysts' average 12-month price target for ResMed is 246.89, 4.9% above the current price of 235.26. Their targets range from 213.00 to 300.00.
Of the 11 firms that rated ResMed in the past 12 months, 3 rate it buy or strong buy, 8 hold and 0 sell or strong sell (each firm at its latest rating): a Hold consensus.
Analysts' 1-year price targets range from 213.00 to 300.00, with an average of 246.89.
| Strong buy | 0 | |
| Buy | 3 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong sell | 0 |
12-month price target
| Highest target | 300.00 |
| Average target | 246.89 |
| Lowest target | 213.00 |
| Current price | 235.26 |
ResMed price target history
Have analysts recently raised or lowered their ResMed price target and rating?
How analysts rate ResMed, month by month
3 of 11 firms rate it buy now, against 7 of 11 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
ResMed analyst upgrades, downgrades and price targets
The latest rating change came on 2 November 2026, when Canaccord Genuity downgraded ResMed from Buy to Hold. The most recent new target came from Mizuho Securities on 30 October 2026: 270.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 2 Nov 2026 | Canaccord Genuity | Downgraded · Buy → Hold | — | — | — |
| 30 Oct 2026 | Mizuho Securities Anthony Petrone | — | 240.00 → 270.00 | +12.5% | 252.83 |
| 13 Oct 2026 | Mizuho Securities Anthony Petrone | — | 220.00 → 240.00 | +9.1% | 234.60 |
| 15 Sept 2026 | RBC Capital Craig Wong-Pan | Upgraded · Sector Perform → Outperform | 234.00 → 262.00 | +12.0% | 222.99 |
| 31 Aug 2026 | KeyBanc | Reiterated · Overweight | 255.00 → 267.00 | +4.7% | 240.33 |
| 19 Aug 2026 | Redburn Partners | — | 230.00 | — | 219.98 |
| 7 Aug 2026 | Robert W. Baird | — | 225.00 → 213.00 | -5.3% | 212.39 |
| 7 Aug 2026 | KeyBanc | Reiterated · Overweight | 266.00 → 255.00 | -4.1% | 223.24 |
| 21 Jul 2026 | UBS David Low | — | 345.00 → 300.00 | -13.0% | 195.97 |
| 16 Jul 2026 | RBC Capital | — | 276.00 → 234.00 | -15.2% | 198.57 |
| 15 Jul 2026 | Mizuho Securities | Reiterated · Outperform | 220.00 | — | 193.01 |
| 13 Jul 2026 | Citigroup | Downgraded · Buy → Neutral | — | — | — |
| 10 Jul 2026 | Jefferies | Reiterated · Hold | 225.00 | — | 204.50 |
| 8 Jul 2026 | RBC Capital | Reiterated · Outperform | 314.00 → 276.00 | -12.1% | 219.75 |
| 8 Jul 2026 | Wells Fargo | Reiterated · Equal Weight | 280.00 → 225.00 | -19.6% | 219.75 |
| 22 Jun 2026 | KeyBanc | Reiterated · Overweight | 290.00 → 266.00 | -8.3% | 188.63 |
| 17 Jun 2026 | Morgan Stanley David Bailey | Downgraded · Overweight → Equal Weight | 305.00 → 230.00 | -24.6% | 193.94 |
| 1 May 2026 | Robert W. Baird | — | 281.00 → 225.00 | -19.9% | 203.87 |
| 27 Apr 2026 | KeyBanc | Reiterated · Overweight | 302.00 → 290.00 | -4.0% | 219.85 |
| 13 Apr 2026 | Evercore ISI Anthony Petrone | — | 255.00 | — | 228.33 |
| 30 Jan 2026 | RBC Capital Craig Wong-Pan | Reiterated · Outperform | 314.00 | — | 254.08 |
| 30 Jan 2026 | Stifel Nicolaus | Reiterated · Hold | 260.00 → 265.00 | +1.9% | 257.61 |
| 30 Jan 2026 | KeyBanc Brett Fishbin | — | 299.00 → 302.00 | +1.0% | 257.61 |
| 30 Jan 2026 | Robert W. Baird | — | 275.00 → 281.00 | +2.2% | 257.61 |
| 30 Jan 2026 | Piper Sandler | Reiterated · Neutral | 260.00 → 275.00 | +5.8% | 257.61 |
| 18 Dec 2025 | Stifel Nicolaus Jonathan Block | Reiterated · Hold | 240.00 → 260.00 | +8.3% | 245.94 |
| 16 Dec 2025 | Robert W. Baird | — | 300.00 → 275.00 | -8.3% | 253.07 |
| 16 Dec 2025 | Baird | Downgraded · Outperform → Neutral | — | — | — |
| 12 Dec 2025 | UBS Marcus Curley | — | 345.00 | — | 251.38 |
ResMed EPS and revenue estimates
Analysts expect ResMed's EPS to grow 11.7% a year until 2029, slower than over the last 5 years (26.3% a year) and the last 3 years (19.5%).
Analysts expect ResMed's revenue to grow 5.3% a year until 2029, slower than over the last 5 years (12.1% a year) and the last 3 years (10.2%).
Revenue
EPS
Does ResMed beat earnings estimates?
On average, analysts' EPS estimate was 4.1% off the result, either way, and their revenue estimate 1.1%, over the last 12 quarters.
- EPS beats
- 74 / 123
- Revenue beats
- 77 / 122
- Average EPS surprise, last 12
- +4.1%
- Since
- May 1996
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 29 Oct 2026 | 2.69 | 2.91 | +8.2% | 1.39B | 1.41B | +1.5% |
| Q4 FY2026 | 6 Aug 2026 | 2.89 | 2.95 | +2.1% | 1.46B | 1.46B | +0.2% |
| Q3 FY2026 | 30 Apr 2026 | 2.80 | 2.86 | +2.1% | 1.42B | 1.43B | +0.8% |
| Q2 FY2026 | 29 Jan 2026 | 2.74 | 2.81 | +2.6% | 1.40B | 1.42B | +1.6% |
| Q1 FY2026 | 30 Oct 2025 | 2.51 | 2.55 | +1.6% | 1.33B | 1.34B | +0.2% |
| Q4 FY2025 | 31 Jul 2025 | 2.46 | 2.55 | +3.7% | 1.33B | 1.35B | +1.3% |
| Q3 FY2025 | 23 Apr 2025 | 2.38 | 2.37 | -0.4% | 1.29B | 1.29B | +0.3% |
| Q2 FY2025 | 30 Jan 2025 | 2.32 | 2.43 | +4.7% | 1.27B | 1.28B | +1.2% |
| Q1 FY2025 | 24 Oct 2024 | 2.04 | 2.20 | +7.8% | 1.19B | 1.22B | +3.3% |
| Q4 FY2024 | 1 Aug 2024 | 2.07 | 2.08 | +0.5% | 1.22B | 1.22B | +0.4% |
| Q3 FY2024 | 25 Apr 2024 | 1.91 | 2.13 | +11.5% | 1.17B | 1.20B | +1.9% |
| Q2 FY2024 | 24 Jan 2024 | 1.80 | 1.88 | +4.4% | 1.15B | 1.16B | +1.1% |
ResMed stock price 2027–2031: scenarios
If ResMed's earnings keep growing at the 9.1% a year analysts expect to FY2029, it would earn about 17.25 a share in FY2031. At the P/E it has traded at over the last five years (18.7 to 39.3) that is 321.93 to 677.03 a share, or 509.04 at its average P/E of 29.5. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2027 | 12.13 | 226.35 | 357.90 | 476.01 |
| FY2028 | 13.24 | 247.11 | 390.73 | 519.69 |
| FY2029 | 14.50 | 270.59 | 427.85 | 569.05 |
| FY2030 (extrapolated) | 15.81 | 295.15 | 466.68 | 620.70 |
| FY2031 (extrapolated) | 17.25 | 321.93 | 509.04 | 677.03 |
Each year's EPS is the analysts' consensus to FY2029; the years after continue its 9.1% a year. Bear, base and bull apply the lowest, average and highest P/E of the last five fiscal year ends (18.7, 29.5, 39.3).
Is ResMed stock undervalued or overvalued?
ResMed's P/E of 21.4 is near the bottom of its 5-year range (17.6 to 75.4, median 28.6). Analysts expect slower growth than in recent years, so the low P/E may be deserved. Buyers pay more for each point of growth than usual: a PEG of 1.8 on expected growth against 1.1 on its median P/E and past five years' growth. At its usual P/E (28.1 × EPS of 10.48), ResMed's fair value is 294.55; the price, 235.26, is 20.1% below it. The EPS is without 0.51 a share of one-off gains in its other income, which the business does not repeat. Its forward P/E, on the consensus for FY2027, is 19.4.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (17.6 and 45.6). The price against its P/E range
- Price to earnings ratio (TTM)
- 21.41
- Five-year median P/E
- 28.59
- Five-year P/E range
- 17.6 – 75.4
- Forward P/E (FY2027)
- 19.40
- PEG ratio
- 2.36
- To the average target
- +4.9%
Most undervalued US stocks
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 195.09146Price 99.09244 | +96.9% | |
| 186.680 | 359.93270Price 186.68450 | +92.8% | |
| 213.670 | 405.66304Price 213.67507 | +89.9% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 42.225 | 79.0244Price 42.23157 | +87.1% | |
| 160.650 | 299.85225Price 160.65375 | +86.6% | |
| 108.445 | 201.41108Price 108.45248 | +85.7% |
Furthest below the fair value on each stock's page, updated every day.